MJosé Juan, Attending Physician Medical Oncologist at Fundación Instituto Valenciano de Oncología, shared on X:
“In EV-treated mUC, membranous-but not cytoplasmic – NECTIN4 predicts benefit, while amplification identifies great responders ORR:
76.2% →42.9% →26.1% Amplified >non-amplified/membrane-high>membrane-low Membrane matters most.”
Title: Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
Authors: Niklas Klümper, Thomas Büttner, Sebastian Rauch, Stefanie Zschäbitz, Florian Roghmann, Christian Bolenz, Fabienne Lange, Patricia Rausch, Friedemann Zengerling, Nadine Gaisa, Oliver Hahn, Constantin Schwab, Anna Scherping, Marieta Toma, Hendrik Heers, Phillipp Ivanyi, Guenter Niegisch, Camilla Marisa. Grunewald, Christopher Darr, Pia Paffenholz, Richard Weiten, Susanne Füssel, Christian Thomas, Marcus Sondermann, Ulrich Sommer, Kerstin Junker, Katrin Schlack, Jozefina Casuscelli, Can Aydogdu, Dora Niedersüß-Beke, Steffen Rausch, Christoph Kuppe, Joshua Meeks, Bonnie Choy, Sarmad Sadeghi, Parkash Gill, Manuel Ritter, Johannes Brägelmann, Michael Hölzel, Arndt Hartmann, Viktor Grünwald, Jonas Saal, Markus Eckstein
You can also read:
AVENANCE: Real-World Avelumab Maintenance in Advanced Urothelial Carcinoma
